Multiple Myeloma Clinical Trials in Chapel Hill, North Carolina

18 studies are recruiting for multiple myeloma in Chapel Hill, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of North Carolina Medical Center, Chapel Hill, North Carolina
    Locations
    52 in total
    Run by
    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT06297226 on ClinicalTrials.gov

  2. A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

    Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill, North Carolina
    Locations
    50 in total
    Run by
    AbbVie

    See if you can join NCT06953960 on ClinicalTrials.gov

  3. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

    Stage
    Phase 2
    Ages
    12 and older
    Site
    Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
    Locations
    181 in total
    Run by
    American Society of Clinical Oncology

    See if you can join NCT02693535 on ClinicalTrials.gov

  4. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of North Carolina, Chapel Hill, North Carolina
    Locations
    144 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT07258511 on ClinicalTrials.gov

  5. A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

    The study consists of three parts: * Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). *…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    GSK Investigational Site, Chapel Hill, North Carolina
    Locations
    44 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT05714839 on ClinicalTrials.gov

  6. DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

    The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatm…

    Stage
    Not phased
    Ages
    60 and older
    Site
    Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina
    Run by
    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06296368 on ClinicalTrials.gov

  7. A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

    Stage
    Phase 2
    Ages
    18 and older
    Site
    UNC Hospitals Adult Oncology Clinics, Chapel Hill, North Carolina
    Locations
    21 in total
    Run by
    C4 Therapeutics, Inc.

    See if you can join NCT07284758 on ClinicalTrials.gov

  8. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

    Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapse…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill, North Carolina
    Locations
    34 in total
    Run by
    AbbVie

    See if you can join NCT06892522 on ClinicalTrials.gov

  9. Selinexor and Backbone Treatments of Multiple Myeloma Patients

    This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to b…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of North Carolina - Chapel Hill Comprehensive Cancer Center, Chapel Hill, North Carolina
    Locations
    25 in total
    Run by
    Karyopharm Therapeutics Inc

    See if you can join NCT02343042 on ClinicalTrials.gov

  10. A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of North Carolina /ID# 251203, Chapel Hill, North Carolina
    Locations
    46 in total
    Run by
    AbbVie

    See if you can join NCT05650632 on ClinicalTrials.gov

  11. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that r…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
    Locations
    42 in total
    Run by
    Regeneron Pharmaceuticals

    See if you can join NCT05137054 on ClinicalTrials.gov

  12. A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

    The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whethe…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of North Carolina (Data Collection Only), Chapel Hill, North Carolina
    Locations
    11 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06083922 on ClinicalTrials.gov

  13. A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill, North Carolina
    Locations
    49 in total
    Run by
    AbbVie

    See if you can join NCT07095452 on ClinicalTrials.gov

  14. Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

    This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used t…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
    Locations
    5 in total
    Run by
    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT05145400 on ClinicalTrials.gov

  15. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

    This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

    Stage
    Phase 1
    Ages
    13 and older
    Site
    University of North Carolina, Chapel Hill, North Carolina
    Locations
    8 in total
    Run by
    Newave Pharmaceutical Inc

    See if you can join NCT04771572 on ClinicalTrials.gov

  16. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

    Stage
    Phase 1
    Ages
    12 and older
    Site
    UNC Hospital, Chapel Hill, North Carolina
    Locations
    104 in total
    Run by
    Sumitomo Pharma America, Inc.

    See if you can join NCT04988555 on ClinicalTrials.gov

  17. Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

    The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Univeristy of North Carolina at Chapel Hill, Chapel Hill, North Carolina
    Locations
    7 in total
    Run by
    Carevive Systems, Inc.

    See if you can join NCT05974150 on ClinicalTrials.gov

  18. Registry for Adults With Plasma Cell Disorders (PCD's)

    The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives includ…

    Stage
    Not phased
    Ages
    18 and older
    Site
    North Carolina Cancer Hospital, Chapel Hill, North Carolina
    Run by
    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT03717844 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.